CARLSBAD, Calif., Dec. 12 /PRNewswire-FirstCall/ -- The Immune Response Corporation , an immuno-pharmaceutical company focused on developing products to treat autoimmune and infectious diseases, announced that Dr. Joseph O'Neill, President and CEO, will present an overview of the Company's immune-based therapies, currently in Phase II clinical trials, at the New York Society of Security Analysts (NYSSA) 10th Annual Biotech/Specialty Pharma Industry Conference in New York City.
The Company's presentation to the NYSSA will take place today, December 12, 2006, at 4:30 p.m. (EST). A live webcast of this presentation will be available at http://www.shareholder.com/imnr/MediaRegister.cfm?MediaID=23194. The online replay will be available for 30 days after the presentation.
Dr. O'Neill will discuss a key strategic agreement with Accelsiors CRO & Consultancy Services, a clinical research organization (CRO) with extensive experience in conducting multiple sclerosis (MS) trials, to oversee a 200-patient Phase IIb trial of NeuroVax(TM), an investigational T-cell receptor (TCR) peptide vaccine for the treatment of MS. He will review the Company's drug development pipeline and status of the Phase II clinical trials in progress for NeuroVax(TM) and for IR103, for the treatment of human immunodeficiency virus (HIV). IR103 is based on the Company's patented whole-inactivated virus technology, co-invented by Dr. Jonas Salk.
"By harnessing the body's own defenses to control disease, NeuroVax(TM) and IR103 potentially offer important clinical advances for patients suffering from MS and HIV," said Dr. O'Neill. "Our goal is for these immune based therapies to benefit the millions of patients in need of more effective and tolerable treatment options."
About The Immune Response Corporation
The Immune Response Corporation is an immuno-pharmaceutical company focused on developing products to treat autoimmune and infectious diseases. The Company's lead immune-based therapeutic product candidates are NeuroVax(TM) for the treatment of MS and IR103 for the treatment of HIV infection. Both of these therapies are in Phase II clinical development and are designed to stimulate disease pathogen-specific immune responses aimed at slowing or halting the rate of disease progression.
NeuroVax(TM), which is based on the Company's patented T-cell receptor (TCR) peptide vaccine technology, has shown potential clinical value in the treatment of relapsing forms of MS. NeuroVax(TM) has been shown to stimulate strong, disease-specific cell-mediated immunity in nearly all patients treated and appears to work by enhancing levels of FOXP3+ Treg cells that are able to down regulate the activity of pathogenic T-cells that cause MS. Increasing scientific findings have associated diminished levels of FOXP3+ Treg cell responses with the pathogenesis and progression of MS and other autoimmune diseases such as rheumatoid arthritis (RA), psoriasis and Crohn's disease. In addition to MS, the Company has open Investigational New Drug Applications (IND) with the FDA for clinical evaluation of TCR peptide-based immune-based therapies for RA and psoriasis.
IR103 is based on the Company's patented, whole-inactivated virus technology, co-invented by Dr. Jonas Salk and indicated to be safe and immunogenic in extensive clinical studies of Remune(R), the Company's first generation HIV product candidate. IR103 is a more potent formulation that combines its whole-inactivated antigen with a synthetic Toll-like receptor (TLR-9) agonist with the intent to create enhanced HIV-specific immune responses. The Company is currently testing IR103 in two Phase II clinical studies as a first-line treatment for drug-naive HIV-infected individuals not yet eligible for antiretroviral therapy according to current medical guidelines. NeuroVax(TM) and IR103 are in clinical development by The Immune Response Corporation and are not approved by any regulatory agencies in any country at this time. Please visit The Immune Response Corporation at www.imnr.com.
This news release contains forward-looking statements. Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing. Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of NeuroVax(TM) or IR103, the uncertainty of successful completion of any such clinical trials, the fact that the Company has not succeeded in commercializing any drug, the risk that NeuroVax(TM) or IR103 might not prove to be effective as either a therapeutic or preventive vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of NeuroVax(TM) or IR103 in preclinical trials and/or earlier clinical trials. A more extensive set of risks is set forth in The Immune Response Corporation's SEC filings including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2005, and its subsequent Quarterly Reports filed on Form 10-Q. The Company undertakes no obligation to update the results of these forward-looking statements to reflect events or circumstances after today or to reflect the occurrence of unanticipated events.
Remune(R) is a registered trademark of The Immune Response Corporation. NeuroVax(TM) is a trademark of The Immune Response Corporation.
INVESTOR CONTACT: COMPANY CONTACT:
Gene Marbach Michael K. Green, COO and CFO
Makovsky & Company The Immune Response Corporation
(212) 508-9645 (760) 431-7080
The Immune Response Corporation